ENTA – Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc.ENTA
$7.50Name : Enanta Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $160,324,496.00
EPSttm : -4.53
Enanta Pharmaceuticals, Inc.
$7.50
0.13%$0.01Float Short %
12.58
Margin Of Safety %
Put/Call OI Ratio
0.09
EPS Next Q Diff
-0.01
EPS Last/This Y
1.59
EPS This/Next Y
0.65
Price
7.48
Target Price
15.2
Analyst Recom
2.4
Performance Q
27.99
Relative Volume
1.25
Beta
0.83
Ticker: ENTA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | ENTA | 6.29 | 0.13 | 0.00 | 1104 |
| 2025-06-03 | ENTA | 7.18 | 0.13 | 0.00 | 1105 |
| 2025-06-04 | ENTA | 7.1 | 0.11 | 0.50 | 1220 |
| 2025-06-05 | ENTA | 7.19 | 0.11 | 0.00 | 1221 |
| 2025-06-06 | ENTA | 7.43 | 0.11 | 0.00 | 1231 |
| 2025-06-09 | ENTA | 7.5 | 0.11 | 0.00 | 1232 |
| 2025-06-10 | ENTA | 7.56 | 0.11 | 0.00 | 1229 |
| 2025-06-11 | ENTA | 7.94 | 0.11 | 0.07 | 1229 |
| 2025-06-12 | ENTA | 7.4 | 0.11 | 1.18 | 1300 |
| 2025-06-13 | ENTA | 7.51 | 0.12 | 0.00 | 1311 |
| 2025-06-16 | ENTA | 7.28 | 0.12 | 0.03 | 1310 |
| 2025-06-17 | ENTA | 7.04 | 0.13 | 0.00 | 1283 |
| 2025-06-18 | ENTA | 7.22 | 0.13 | 0.00 | 1283 |
| 2025-06-20 | ENTA | 7.22 | 0.13 | 0.00 | 1285 |
| 2025-06-23 | ENTA | 7.08 | 0.09 | 0.00 | 1170 |
| 2025-06-24 | ENTA | 7.32 | 0.09 | 0.00 | 1206 |
| 2025-06-25 | ENTA | 7.44 | 0.09 | 0.77 | 1208 |
| 2025-06-26 | ENTA | 7.53 | 0.10 | 0.00 | 1231 |
| 2025-06-27 | ENTA | 7.48 | 0.09 | 0.10 | 1234 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | ENTA | 6.31 | 24.3 | - | -3.89 |
| 2025-06-03 | ENTA | 7.19 | 24.3 | - | -3.89 |
| 2025-06-04 | ENTA | 7.10 | 24.3 | - | -3.89 |
| 2025-06-05 | ENTA | 7.21 | 24.3 | - | -3.89 |
| 2025-06-06 | ENTA | 7.43 | 24.3 | - | -3.89 |
| 2025-06-09 | ENTA | 7.50 | 24.3 | - | -3.89 |
| 2025-06-10 | ENTA | 7.57 | 24.3 | - | -3.89 |
| 2025-06-11 | ENTA | 7.97 | 24.3 | - | -3.89 |
| 2025-06-12 | ENTA | 7.41 | 24.3 | - | -3.89 |
| 2025-06-13 | ENTA | 7.52 | 24.3 | - | -3.89 |
| 2025-06-16 | ENTA | 7.26 | 24.3 | - | -3.89 |
| 2025-06-17 | ENTA | 7.04 | 24.3 | - | -3.89 |
| 2025-06-18 | ENTA | 7.23 | 24.3 | - | -3.89 |
| 2025-06-20 | ENTA | 7.18 | 24.3 | - | -3.89 |
| 2025-06-23 | ENTA | 7.09 | 24.3 | - | -3.89 |
| 2025-06-24 | ENTA | 7.31 | 24.3 | - | -3.89 |
| 2025-06-25 | ENTA | 7.44 | 24.3 | - | -3.89 |
| 2025-06-26 | ENTA | 7.50 | 24.3 | - | -3.89 |
| 2025-06-27 | ENTA | 7.48 | 24.3 | - | -3.89 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | ENTA | 1.97 | -8.62 | 14.37 |
| 2025-06-03 | ENTA | 1.97 | -8.62 | 14.37 |
| 2025-06-04 | ENTA | 1.97 | -8.62 | 14.37 |
| 2025-06-05 | ENTA | 1.97 | -8.62 | 14.37 |
| 2025-06-06 | ENTA | 1.97 | -8.62 | 14.37 |
| 2025-06-09 | ENTA | 1.97 | -8.65 | 14.37 |
| 2025-06-11 | ENTA | 3.06 | -8.65 | 13.70 |
| 2025-06-12 | ENTA | 3.06 | -8.65 | 13.70 |
| 2025-06-13 | ENTA | 3.06 | -8.65 | 13.70 |
| 2025-06-16 | ENTA | 3.06 | -8.65 | 13.70 |
| 2025-06-17 | ENTA | 3.06 | -8.65 | 13.70 |
| 2025-06-18 | ENTA | 3.06 | -8.65 | 13.70 |
| 2025-06-19 | ENTA | 3.06 | -8.65 | 13.70 |
| 2025-06-20 | ENTA | 3.06 | -8.65 | 13.70 |
| 2025-06-24 | ENTA | 3.06 | -8.63 | 13.70 |
| 2025-06-25 | ENTA | 3.06 | -8.63 | 13.70 |
| 2025-06-26 | ENTA | 3.06 | -8.63 | 12.58 |
| 2025-06-27 | ENTA | 3.06 | -8.63 | 12.58 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.06
Avg. EPS Est. Current Quarter
-0.81
Avg. EPS Est. Next Quarter
-1.07
Insider Transactions
3.06
Institutional Transactions
-8.63
Beta
0.83
Average Sales Estimate Current Quarter
16
Average Sales Estimate Next Quarter
14
Fair Value
Quality Score
23
Growth Score
28
Sentiment Score
47
Actual DrawDown %
92.7
Max Drawdown 5-Year %
-95.6
Target Price
15.2
P/E
Forward P/E
PEG
P/S
2.49
P/B
1.71
P/Free Cash Flow
EPS
-4.54
Average EPS Est. Cur. Y
-3.89
EPS Next Y. (Est.)
-3.25
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-149.57
Relative Volume
1.25
Return on Equity vs Sector %
-127
Return on Equity vs Industry %
-109.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.53
EBIT Estimation
Enanta Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 131
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today
news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance
stock history ENTA – Enanta Pharmaceuticals Inc invest stock market
stock prices ENTA premarket after hours
ticker ENTA fair value insiders trading